MedTrace Logo

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

NCT03916913 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2019-04-17

No results posted yet for this study

Summary

In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.

Conditions

  • Non-Small Cell Lung Cancer Metastatic

Interventions

RADIATION

Local radiation therapy

Local radiotherapy on all sites of disease including primary and metastatic lesions

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jingbo Wang, MD · Cancer Hospital, CAMS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2022-01-01
Completion
2023-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03916913 on ClinicalTrials.gov